share_log

Bee Vectoring Technologies Announces First Sale of CR-7 to BioSafe for Foliar Application

Bee Vectoring Technologies Announces First Sale of CR-7 to BioSafe for Foliar Application

Bee Vectoring Technologies宣佈首次向BioSafe出售用於葉面施用的CR-
newsfile ·  2023/09/28 20:00

Mississauga, Ontario and Sacramento, California--(Newsfile Corp. - September 28, 2023) - Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF) (CVE: BEE) (the "Company" or "BVT") is pleased to announce its first sales order of BVT's Clonostachys rosea CR-7 (CR-7) proprietary microbe for use in the foliar application market. This groundbreaking deal is with BioSafe Systems, an industry leader in environmentally sustainable products. This is the result of an earlier announcement of a commercial agreement between BVT and BioSafe to develop and market end-use biological products for plant health and control of foliar and soil diseases.

安大略省密西索加和加利福尼亞州薩克拉門託-(新聞檔案公司-2023年9月28日)-蜜蜂向量化技術國際公司。(CSE:BEE)(OTCQB:BEVVF)(CVE:BEE)(“公司”或“BVT”)很高興宣佈BVT的第一個銷售訂單華支睪吸蟲CR-7(CR-7)用於葉面應用市場的專有微生物。這項突破性的協定是與環境可持續產品的行業領先者BioSafe Systems達成的。這是BVT和BioSafe早些時候宣佈的一項商業協定的結果,BVT和BioSafe將開發和銷售用於植物健康和控制葉片和土壤疾病的最終用途生物製品。

"Not only is this BVT's first sale to a larger Ag-inputs company, it's also an entry into a totally new market and revenue source, giving us access to markets where bees are not used for the first time," said Ashish Malik, CEO of BVT. "This confirms that our strategy to expand business to channel partners like BioSafe is working well and paying dividends, as it enables us to scale growth and expand market share much more quickly."

BVT首席執行官阿希什·馬利克表示:“這不僅是BVT第一次出售給規模更大的農業投入品公司,也是進入一個全新的市場和收入來源,使我們能夠進入首次不使用蜜蜂的市場。”這證實了我們向BioSafe這樣的渠道合作夥伴擴展業務的戰略運作良好,並正在產生紅利,因為它使我們能夠更快地擴大增長和擴大市場份額。“

This inaugural sale of technical-grade CR-7 marks BVT's entry into the foliar business. BioSafe will take CR-7, use it to create a proprietary formulation and sell it to their distribution network in the foliar market. BVT will receive a royalty for every BioSafe sale.

此次技術級CR-7的首次銷售標誌著BVT進入了葉類業務。Biosafe將使用CR-7,用它來創造一種專有配方,並將其出售給他們在葉類市場的分銷網路。BVT將從每一筆BioSafe銷售中獲得版稅。

"We've also just finished characterizing CR-7 for the control of various diseases across multiple crops," said Dr. Mason Newark, Field Technical Manager at BVT. "This validates CR-7 as a broad-spectrum biofungicide across many crops and creates a solid foundation for building up our foliar business."

BVT的現場技術經理梅森·紐瓦克博士說:“我們也剛剛完成了CR-7的特性,用於控制多種作物的各種疾病。這證實了CR-7是一種適用於許多作物的廣譜生物殺菌劑,並為我們建立葉類業務奠定了堅實的基礎。“

The deal with BioSafe is a key milestone in BVT's ongoing corporate expansion strategy. "Entering the foliar business expands our market in exciting new ways," said Mr. Malik. "It demonstrates successful execution of our business strategy, which is to focus on both geographic expansion and finding new applications for CR-7."

與BioSafe的交易是BVT正在進行的公司擴張戰略中的一個關鍵里程碑。馬利克說:“進軍葉菜行業,以令人興奮的新方式拓展了我們的市場。”它證明瞭我們的業務戰略的成功執行,即專注於地域擴張和為CR-7尋找新的應用。“

About Bee Vectoring Technologies International Inc.
BVT, an agriculture technology company, is a market disruptor with a significant global market opportunity in the $240 billion crop protection and fertilizer market. BVT has pioneered a natural precision agriculture system that replaces chemical pesticides and wasteful plant protection product spray applications by delivering biological pesticide alternatives to crops using commercially grown bees. BVT's award-winning technology, precision vectoring, is completely harmless to bees and allows minute amounts of naturally-derived pesticides (called biologicals) to be delivered directly to blooms, providing improved crop protection and yield results than traditional chemical pesticides – and improving the health of the soil, the microbiome and the environment. Currently, BVT has over 55 granted patents, over 35 patents pending in all major agricultural countries worldwide and has US EPA registration of its Vectorite with CR-7 (EPA Registration No. 90641-2) for sale as a registered biological fungicide for use on the labeled crops.

關於蜜蜂向量化技術國際公司
BVT是一家農業技術公司,在2400億美元的作物保護和化肥市場上具有巨大的全球市場機會,是市場顛覆者。BVT開創了一種天然精準農業系統,通過使用商業培育的蜜蜂為作物提供生物農藥替代品,取代了化學農藥和浪費的植物保護產品噴霧應用。BVT的獲獎技術精密向量化對蜜蜂完全無害,允許微量的天然衍生殺蟲劑(稱為生物製品)直接輸送到花朵中,提供比傳統化學殺蟲劑更好的作物保護和產量結果-並改善土壤、微生物群和環境的健康。目前,BVT已授予超過55項專利,在全球所有主要農業國家都有超過35項正在申請的專利,並已在美國環保局將其Vectorite在CR-7中註冊(環保局註冊號90641-2),作為註冊生物殺菌劑出售,用於標籤作物。

Additional information can be viewed at the Company's website . To receive regular news updates from the Company, subscribe at .

欲瞭解更多資訊,請訪問公司網站。要定期接收公司的最新新聞,請訂閱。

BVT Company Contact:
Ashish Malik, President & CEO, BVT
info@beevt.com

BVT公司聯繫人:
阿什什·馬利克,總裁,BVT首席執行官
郵箱:info@beevt.com

BVT Investor Contact:
Babak Pedram
Virtus Advisory Group
Tel: 416-995-8651
bpedram@virtusadvisory.com

BVT投資者聯繫人:
巴布克·佩德拉姆
Virtus顧問團
電話:416-995-8651
郵箱:bpedram@virtusvisory.com

The CSE has neither approved nor disapproved the contents of this press release. The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, "annual revenue potential", are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: planted acres, selling price of competitive chemical pesticides and the US to Canadian dollar exchange rate. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include changes in law, competition, litigation, the ability to implement business strategies and pursue business opportunities, state of the capital markets, the availability of funds and resources to pursue operations, new technologies, the ability to protect intellectual property rights, the ability to obtain patent protection for products, third-party intellectual property infringement claims, regulatory changes affecting products, failing research and development activities, the ability to reach and sustain profitability, dependence on business and technical experts, the ability to effectively manage business operations and growth, issuance of debt, dilution of existing securities, volatility of publicly traded securities, potential conflicts of interest, unlikelihood of dividend payments, the potential costs stemming from defending third-party intellectual property infringement claims, the ability to secure relationships with manufacturers and purchasers, as well as general economic, market and business conditions, as well as those risk factors discussed or referred to in the Company's Filing Statement dated August 14,2020, filed with the CSE and securities regulatory authorities in certain provinces of Canada and available at . Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. All figures are in Canadian dollars.

CSE既沒有批准也沒有反對本新聞稿的內容。CSE不對本新聞稿的充分性或準確性承擔責任。本新聞稿中包含的某些陳述構成“前瞻性資訊”,這一術語在適用的加拿大證券法中有定義。“可能”、“應該”、“潛在”、“將”、“尋求”、“打算”、“計劃”、“預期”、“相信”、“估計”、“預期”以及與公司有關的類似表述“年度收入潛力”,旨在識別前瞻性資訊。除歷史事實以外的所有陳述都可能是前瞻性資訊。此類陳述反映了公司目前對未來事件的看法和意圖,以及公司目前掌握的資訊,受某些風險、不確定因素和假設的影響,這些風險、不確定因素和假設包括:種植面積、有競爭力的化學殺蟲劑的銷售價格以及美元對加拿大元的匯率。在提供前瞻性資訊時採用了重大因素或假設。如果這些風險或不確定性中的一個或多個成為現實,許多因素可能會導致這些前瞻性資訊可能表達或暗示的實際結果、業績或成就與本文描述的結果、業績或成就不同。這些因素包括法律的變化、競爭、訴訟、實施商業戰略和尋求商業機會的能力、資本市場的狀況、開展業務的資金和資源的可獲得性、新技術、保護知識產權的能力、獲得產品專利保護的能力、第三方知識產權侵權索賠、影響產品的監管變化、研發活動失敗、達到和維持盈利的能力、對商業和技術專家的依賴、有效管理業務運營和增長的能力、債務發行、現有證券的稀釋、上市證券的波動性、潛在的利益衝突、不可能支付股息。為第三方知識產權侵權索賠辯護的潛在成本、確保與製造商和採購商的關係的能力、一般經濟、市場和商業條件,以及公司於2020年8月14日提交給加拿大某些省份的CSE和證券監管機構的備案聲明中討論或提到的風險因素,可在上查閱。如果任何因素以意想不到的方式影響公司,或者前瞻性資訊背後的假設被證明是不正確的,實際結果或事件可能與預測的結果或事件大不相同。任何此類前瞻性資訊都明確地受到本警示聲明的限制。此外,公司不對此類前瞻性資訊的準確性或完整性承擔責任。本新聞稿中包含的前瞻性資訊是截至本新聞稿發佈之日的資訊,除適用法律要求外,公司沒有義務公開更新或修改任何前瞻性資訊。所有數位都是以加元計算的。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論